Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.
BACKGROUND
Atrial fibrillation (AF) is the most common arrhythmia to occur after cardiac surgery. An exaggerated inflammatory response has been proposed to be one etiological factor.


OBJECTIVE
To test whether intravenous corticosteroid administration after cardiac surgery prevents AF after cardiac surgery.


METHODS
A double-blind, randomized multicenter trial (study enrollment August 2005-June 2006) in 3 university hospitals in Finland of 241 consecutive patients without prior AF or flutter and scheduled to undergo first on-pump coronary artery bypass graft (CABG) surgery, aortic valve replacement, or combined CABG surgery and aortic valve replacement.


METHODS
Patients were randomized to receive either 100-mg hydrocortisone or matching placebo as follows: the first dose in the evening of the operative day, then 1 dose every 8 hours during the next 3 days. In addition, all patients received oral metoprolol (50-150 mg/d) titrated to heart rate.


METHODS
Occurrence of AF during the first 84 hours after cardiac surgery.


RESULTS
The incidence of postoperative AF was significantly lower in the hydrocortisone group (36/120 [30%]) than in the placebo group (58/121 [48%]; adjusted hazard ratio, 0.54; 95% confidence interval, 0.35-0.83; P = .004; number needed to treat, 5.6). Compared with placebo, patients receiving hydrocortisone did not have higher rates of superficial or deep wound infections, or other major complications.


CONCLUSIONS
Intravenous hydrocortisone reduced the incidence of AF after cardiac surgery.


BACKGROUND
clinicaltrials.gov Identifier: NCT00442494.
Halonen
Jari
J
Departments of Surgery and Internal Medicine, Kuopio University Hospital, and Computing Center of Kuopio University, Kuopio;
Halonen
Pirjo
P
Järvinen
Otso
O
Taskinen
Panu
P
Auvinen
Tommi
T
Tarkka
Matti
M
Hippeläinen
Mikko
M
Juvonen
Tatu
T
Hartikainen
Juha
J
Hakala
Tapio
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001021:Aortic Valve; D001281:Atrial Fibrillation / Q000209:etiology* / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies
D000893:Anti-Inflammatory Agents; D006854:Hydrocortisone